Novavax, Inc. (NVAX) said the first volunteers have been enrolled in the phase 2 portion of the ongoing clinical trial to evaluate the immunogenicity and safety of NVX-CoV2373, the company's COVID-19 vaccine candidate. The phase 2 portion of the phase 1/2 trial trial expands on the age range of the phase 1 portion by including older adults 60-84 years of age as approximately 50 percent of the trial's population.
In the phase 1 portion of the phase 1/2 clinical trial, conducted in Australia, NVX-CoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera.
Gregory Glenn, President, Research and Development at Novavax, said: "We know that the world is closely watching all of these trials, and we anticipate interim data from this trial in the fourth quarter of this year."
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.